表紙:世界の分子診断市場 - 成長、動向、および予測(2021年 - 2026年)
市場調査レポート
商品コード
546538

世界の分子診断市場 - 成長、動向、および予測(2021年 - 2026年)

Molecular Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 125 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.11円
世界の分子診断市場 - 成長、動向、および予測(2021年 - 2026年)
出版日: 2021年07月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 125 Pages
納期: 2~3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の分子診断市場は、2018年に78億5,445万米ドルとなりました。同市場は、2019年から2024年までの間に9.23%のCAGRで拡大する見通しで、2024年には133億4,035万米ドルまで成長すると予測されています。市場の成長要因には、世界中でのバクテリアおよびウイルス流行の大規模発生、ポイントオブケア診断、薬理ゲノムにおける最近の進歩、および急速に進化する技術などが挙げられます。

当レポートでは世界の分子診断市場について調査しており、市場の動向や機会、成長および阻害要因、技術・用途・製品・エンドユーザー・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査の成果
  • 調査の仮定
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場成長要因
    • 世界での大規模な細菌およびウイルスの流行
    • ポイントオブケア診断の需要の増加
    • 薬理ゲノミクスにおける最近の進歩
    • 急速に進化する技術
  • 市場阻害要因
    • 研究開発および経済減速のための限られた予算
    • 非常に複雑な検査センターの必要性
  • ポーターのファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 業界内の競争

第5章 市場セグメント

  • 技術別
    • In situハイブリダイゼーション
    • チップとマイクロアレイ
    • 質量分析(MS)
    • シーケンス
    • PCR
    • その他の技術
  • 用途別
    • 感染症
    • 腫瘍学
    • 薬理ゲノミクス
    • 微生物学
    • 遺伝病スクリーニング
    • ヒト白血球抗原タイピング
    • 血液スクリーニング
  • 製品
    • 装置
    • 試薬
    • その他
  • エンドユーザー
    • 病院
    • 実験室
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東およびアフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • F. Hoffmann-la Roche Ltd
    • Illumina, Inc.
    • Hologic Corporation
    • Agilent Technologies / Dako
    • Qiagen
    • Myriad Genetics
    • BD (Becton, Dickinson And Company)
    • Abbott Laboratories
    • Cepheid Inc.
    • Genomic Health Inc.

第7章 市場機会および将来動向

目次
Product Code: 47536

The global molecular diagnostics market was valued at USD 9,371 million in 2020, and it is expected to reach 15,196 million by 2026, registering a CAGR of 9.2% during the forecast period.

Globally, the integrated supply chains that ensure better quality, safety, and innovative approaches for distribution across the healthcare sector are tremendously impacted due to the disruption in the distribution channels across the world. The COVID-19 pandemic has turned a spotlight on the molecular diagnostics industry across the world, with the rapid development of diagnostics, fast-tracked regulatory clearances, and ramped-up distribution in various regions to help curb the spread of the virus.

The demand for diagnostic products due to COVID-19 in Brazil is expected to increase mainly due to rising demand for polymerase chain reaction tests, next-generation sequencing (NGS), serology-based rapid-test products, and a sharp rise in the target patient population. For instance, Seegene Inc., a leading developer of multiplex PCR technologies, has supplied five million tests of Allplex 2019-nCOV assay to Brazil through subsidiary Seegene do Brasil Diagnosticos Ltda.

Some of the factors responsible for the growth of the market include large outbreaks of bacterial and viral epidemics in the world, increasing demand for point-of-care diagnostics, recent advancements in pharmacogenomics, and rapidly evolving technology. According to the World Health Organization's (WHO) 2020 fact sheet, in 2019, the largest number of new tuberculosis (TB) cases occurred in the South-East Asian region.

Furthermore, globally, there is an increasing incidence of cancer, which is driving the market growth. For instance, according to the Globocan Database, in 2020, around 19,292,789 new cancer cases and 9,9581,33 deaths due to cancer. Moreover, it is estimated that the number of new cancer cases may grow from 18.1 million to 29.4 million, between 2018 and 2040.

Molecular diagnostics is considered to be the best method to identify and characterize a microorganism. An effective test must be precise, rapid, and also be able to measure the infectious burden. Better testing quickly identifies the organism's strain and drug susceptibility, thus, reducing the delay in finding the right antibiotic. Technological advancements, like a polymerase chain reaction (PCR), have also made it possible to identify the antimicrobial resistance genes and provide public health information, such as strain characterization by genotyping. Hence, from the factors mentioned above, the market is estimated to witness significant growth over the forecast period.

Key Market Trends

Instruments Segment is Expected to Hold Significant Market Share Over the Forecast Period

Molecular diagnostics plays a vital role in the assessment of disease prognosis and therapy response, as well as in the detection of minimal residual disease. In the past decade, molecular diagnostics has grown, due to advances in chemistries and instrumentation, including automation, integration, throughput, and the ability to use the instrumentation in a random-access mode.

The impact of COVID-19 on molecular diagnostics instruments is positive because during the pandemic US FDA has been approved many instruments in the diagnosis of COVID-19. For instance, in July 2020, FDA granted an amendment, to add the Promega Maxwell RSC 48 as an authorized extraction instrument for use with the CDC 2019-nCoV rRT-PCR Diagnostic Panel.

Additionally, in July 2020, Roche Diagnostics India launched the Cobas 8800 instrument at the National Institute of Cholera and Enteric Diseases, Kolkata, and Cobas 6800 at the National Institute for Research in Reproductive Health, Mumbai, to aid with SARS CoV-2 diagnostic testing. Roche's Cobas 6800/8800 systems provide test results in three and half hours and offer improved operating efficiency, flexibility, and fastest time-to-time results.

Some of the sophisticated instruments used in this market are high-performance liquid chromatography (HPLC), mass spectrometry (MS), and nuclear magnetic resonance (NMR), along with real-time PCR, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), lateral flow devices, patient safety syringes, and point-of-care testing devices, among others.

Furthermore, with the tremendous opportunity in in vitro diagnostics, many market players are adopting various strategies, such as collaborations, acquisitions, new products launches, and expansions, into the Asia Pacific Market.

For instance, in January 2020, Illumina received product approval from Pharmaceuticals and Medical Devices Agency (PMDA), Japan for MiSeqDx instrument. This approval allows for the distribution of the MiSeqDx as a Class I medical device in Japan, which shows a positive impact on the market.

In addition, in September 2018, Biocartis Group NV, an innovative molecular diagnostics company, and Guangzhou Wondfo Biotech Co. Ltd, a fast-growing diagnostics leader in China, entered a joint venture aimed at the commercialization of the fully automated molecular diagnostics Idylla platform in mainland China, within the field of oncology. Thus, owing to the factors mentioned above, it is expected to drive market growth over the forecast period.

North America Dominates the Market and is Expected to do the Same over the Forecast Period

Some of the factors driving the market growth include large outbreaks of bacterial and viral epidemics, increasing demand for point-of-care diagnostics, rapidly evolving technology, and the presence of key market players in the region.

During the COVID-19 pandemic, the United States Centers for Disease Control and Prevention (CDC) used a one-step PCR format to diagnose COVID-19. The assay was carried out by isolating RNA from the sample and adding it to the master mix containing forward and reverse primers, nuclease-free water, the reaction mixture (reverse transcriptase, polymerase, nucleotides, magnesium, and other additives). For instance, as per the Centers for Disease Control and Prevention (CDC), in the United States, antigen tests and nucleic acid amplification tests (NAATs) were used as diagnostic tests to detect infection with SARS-CoV-2. Viral tests were used as screening tests to reduce the transmission of SARS-CoV-2 by identifying infected persons who need to isolate from others.

Molecular diagnostics has played a vital role in changing the face of disease diagnostics and assuring speedy detection and accurate care for critically ill patients. The increase in per capita health expenditures, the advancement in healthcare infrastructure, and the increase in the number of infectious diseases and cancer cases in the United States have led to a shift in trend from the traditional diagnostic methods to molecular diagnostics.

The high burden of chronic diseases in all age groups, especially the aging population, may drive the demand for molecular diagnostic tests in Canada. According to the data provided by the Canadian government, in 2019, 44% of adults aged 20+ years have at least 1 of 10 common chronic conditions, and the prevalence of chronic diseases is rising. Additionally, as per the 2018 HIV Surveillance Report, as of 2018, there were around 36.9 million people with HIV in Canada.

Furthermore, rising technological advancements, increasing entry of new players, and speedy adoption of advanced molecular diagnostics are helping in the growth of the market in the United States. Thus, considering above mentioned factors, it is expected to fuel the market growth in North American region over the forecast period.

Competitive Landscape

The global molecular diagnostics market is highly competitive and consists of several major players. However, with technological advancements and product innovations, mid-size to small companies are increasing their market presence by introducing new devices with fewer prices. Some market players include Abbott Laboratories, F Hoffmann-la Roche Ltd, Hologic Corporation, Danaher Corporation, and Agilent Technology, among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Large Outbreaks of Bacterial And Viral Epidemics in the World
    • 4.2.2 Increasing Demand for Point-of-care Diagnostics
    • 4.2.3 Recent Advancements in Pharmacogenomics
    • 4.2.4 Rapidly Evolving Technology
  • 4.3 Market Restraints
    • 4.3.1 Limited Budgets for R&D and Economic Slowdown
    • 4.3.2 Need for High-complexity Testing Centers
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Technology
    • 5.1.1 In Situ Hybridization
    • 5.1.2 Chips and Microarrays
    • 5.1.3 Mass Spectrometry (MS)
    • 5.1.4 Sequencing
    • 5.1.5 PCR
    • 5.1.6 Other Technologies
  • 5.2 By Application
    • 5.2.1 Infectious Disease
    • 5.2.2 Oncology
    • 5.2.3 Pharmacogenomics
    • 5.2.4 Microbiology
    • 5.2.5 Genetic Disease Screening
    • 5.2.6 Human Leukocyte Antigen Typing
    • 5.2.7 Blood Screening
  • 5.3 By Product
    • 5.3.1 Instruments
    • 5.3.2 Reagents
    • 5.3.3 Other Products
  • 5.4 By End User
    • 5.4.1 Hospitals
    • 5.4.2 Laboratories
    • 5.4.3 Other End Users
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 F. Hoffmann-la Roche Ltd
    • 6.1.2 Illumina Ltd
    • 6.1.3 Hologic Corporation
    • 6.1.4 Agilent Technologies, Inc
    • 6.1.5 Qiagen N.V
    • 6.1.6 Myriad Genetics
    • 6.1.7 Becton, Dickinson And Company
    • 6.1.8 Abbott Laboratories
    • 6.1.9 Biomerieux SA
    • 6.1.10 Bio-Rad Laboratories, Inc
    • 6.1.11 Sysmex Corporation
    • 6.1.12 Beckman Coulter, Inc
    • 6.1.13 Thermo Fisher Scientific Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS